Please help TMA speed the time to diagnosis by supporting myositis awareness! Donate Now!
Since 2002, The Myositis Association’s annual research funding program has awarded nearly $8.2 million in research support. We are pleased to announce our 2024 grant awards, funding disease-specific projects in myositis: Our first grant of $80,000 is awarded to Thomas Lloyd, MD, PhD, Chief of Neurology at Baylor College of Medicine, Houston, TX, for his…
Continue Reading
Chimeric antigen receptor T-cell (CAR T-cell) therapy is a process developed to treat certain forms of cancers, especially blood cancers like leukemia and lymphoma. Recently, however, researchers have started exploring its use for autoimmune diseases, including idiopathic inflammatory myositis (IIM). This application is still experimental and not yet available for myositis outside of research studies,…
Continue Reading
Our article about immune boosting supplements raised many questions about the effects of herbal products for those who live with myositis. Such products have been heavily promoted in recent years as remedies for all manner of maladies, including viral and other infections such as colds, flu, and COVID 19. While little or no research has…
Continue Reading
Recently, the FDA announced the approval of a new drug, vamorolone, as a treatment for Duchenne muscular dystrophy (DMD), a genetic muscle disease that usually affects young boys. Understandably, this news hasn’t made a big splash in myositis circles, but it should. Vamorolone, marketed under the name Agamree, is a corticosteroid drug with a twist….
Continue Reading
Octapharma announced today the results from the ProDERM study on the efficacy and safety of Octagam® 10% [Immune Globulin Intravenous (Human)], in adult dermatomyositis (DM) patients have been published in the New England Journal of Medicine (Aggarwal R et al. “Trial of Intravenous Immune Globulin in Dermatomyositis”) Click here for more details
Continue Reading